1. Scrip
  2. >>R&D

EASL Updates: Intercept Says Biomarker Data Bolster OCA’s Case For Fibrosis Benefit

 
• By Joseph Haas

Intercept and Axcella provide updated data on their NASH programs at the International Liver Conference, while CymaBay offers the full dataset for seladelpar in PBC.

DATA_Puzzle Piece_186976547_1200.jpg
Companies presented new data in NASH and PBC at EASL 2020

The European Association for the Study of the Liver’s virtual International Liver Conference kicked off with largely incremental data in therapy areas like non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Among the highlights, Intercept Pharmaceuticals, Inc. reported on 27 August that biomarker data from its Phase III REGENERATE study of obeticholic acid (OCA) in NASH provides further evidence that the drug can provide patients with an improvement in fibrosis, Axcella Health, Inc. presented data on its NASH candidate’s benefits on metabolism, inflammation and fibrosis, and CymaBay Therapeutics, Inc. unveiled final Phase II data for seladelpar in PBC.

Coming off a 29 June complete response letter from the US Food and Drug Administration, Intercept is preparing for a...

More from Clinical Trials

More from R&D

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

 
• By Xu Hu

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.